FDA Brief

Warning letters Drugs

FDA warning letter to

True Chemical Solutions, LLC

MediumIssued Sep 29, 2021Posted Oct 5, 2021Center for Drug Evaluation and Research | CDER

FDA cites True Chemical Solutions over unanswered hand sanitizer records requests.

What happened

FDA sent an electronic request for records on November 10, 2020, under section 704(a)(4) of the FD&C Act (a provision that lets FDA ask for records instead of inspecting), to the contact email in the firm’s registration file. The firm did not answer that request or FDA’s phone calls, and it did not respond to a May 4, 2021 certified-mail follow-up even though delivery was confirmed by signature; FDA said it has no indication of quality assurance for drugs registered at the facility and noted the website shows fracking operations with chemicals that could harm patients if they contaminated drugs.

What FDA found

  1. The firm did not respond to FDA’s November 10, 2020 electronic request for records about its over-the-counter drug manufacturing.

    FD&C Act section 704(a)(4), 21 U.S.C. 374(a)(4)
  2. The firm did not respond to FDA’s May 4, 2021 certified-mail follow-up, even though delivery was confirmed by signature.

    FD&C Act section 704(a)(4), 21 U.S.C. 374(a)(4)
  3. By not providing the requested records, the firm refused to permit access to or copying of records required by section 704(a), which is a prohibited act (illegal under the FD&C Act).

    FD&C Act section 301(e), 21 U.S.C. 331(e); section 704(a)

What FDA wants

Respond within 48 hours to confirm or update your registration and drug listing status and to say whether you will provide the requested records. If you no longer make drugs, delist all drugs using the last lot expiration date as the marketing end date and deregister the facility.

Who should pay attention

  • OTC drug registrants and hand sanitizer manufacturers
  • brands and distributors selling hand sanitizer
  • companies that mix chemical operations with drug manufacturing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Aeroflex Industria de Aerosol Ltda.

    Brazil OTC drug maker Aeroflex ignored FDA records requests, prompting possible approval holds and US shipment refusals.

    High risk
  2. Zhao Qing Longda Biotechnology Co. Ltd.

    FDA says Zhao Qing Longda Biotechnology refused records access for OTC drugs, including children’s toothpaste, and placed its drugs on import alert.

    High risk
  3. KM Pharmaceutical Co. Ltd.

    FDA says KM Pharmaceutical refused to provide drug records and placed all its drugs on import alert.

    High risk
  4. The Anthos Group, Inc.

    Anthos Group refused FDA access to OTC drug records for VERTRA Hand Sanitizer, FDA says.

    Medium